Effective 7/1/2017, Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of drugs – by drug class – that will be considered non-covered, non-preferred brand or require approval from Cigna for coverage, as well as the covered alternatives.

Effective 7/1/2017, Cigna will be making formulary changes that may impact customers at your pharmacy.

Cigna is making a change to the coverage of non-FDA approved topical anti-inflammatory medications effective March 1, 2017.

Effective 1/1/2017, Cigna has made formulary changes that may impact customers at your pharmacy. Cigna will limit the number of preferred drugs in certain drug classes within our formularies. Some drug classes will feature one or a select set of preferred brand name drugs, and other brand name equivalent drugs will only be covered by going through Cigna’s medical necessity review process. We have included a list of drugs – by drug class – that will be considered non-covered or non-preferred brand as of 1/1/17 and their covered alternatives. We sent letters to the customers and prescribers explaining the impact, based on their current medications.

*Please see the attached PDF for more information.

Effective January 1, 2017, CMS will require Medicare plan sponsors to limit the daily cumulative dose of opioid products a member may obtain at Point of Sale (POS). The daily limit is referred to as the Morphine Equivalent Dose (MED) limit. The cumulative limit is based on a combination of drug strength and a product’s Morphine Milligram Equivalency (MME). The cumulative total daily MED value will be calculated based on the number of opioid drugs prescribed over a period of time which includes incoming claims and active claims history.